Skip to content

Tocilizumab-Induced Dermatosis in a Affected person With Rheumatoid Arthritis

Rheumatoid arthritis is a continual systemic autoimmune illness that leads to symmetrical inflammatory polyarthritis with extra-articular involvement, together with pores and skin manifestations. It targets the liner of the synovial membranes and is handled with disease-modifying antirheumatic medication. If left untreated, it results in elevated morbidity, mortality, and socioeconomic burdens. Tocilizumab is a humanized monoclonal antibody that binds to interleukin-6 receptors and is used to deal with rheumatoid arthritis in sufferers with insufficient response to standard artificial remedy. This treatment may cause adversarial dermatologic occasions, corresponding to urticaria, pruritus, and gentle maculopapular rash. On this case, we report a 39-year-old girl with rheumatoid arthritis who developed tocilizumab-induced dermatosis.


Rheumatoid arthritis (RA) is a continual systemic illness that causes inflammatory arthritis and results in progressive, symmetric, and erosive destruction of cartilage and bones. It’s an autoimmune illness characterised by the presence of autoantibody manufacturing, corresponding to rheumatoid issue (RF) and antibodies in opposition to citrullinated peptides (anti-CCP). RA impacts roughly 1% of the inhabitants. Apart from inflammatory arthritis, sufferers could undergo from a number of extra-articular manifestations corresponding to lung illness, heart problems, pores and skin involvement, subcutaneous nodule formation, vasculitis, and inflammatory eye illness [1].,

Pores and skin is incessantly concerned in sufferers with RA, particularly in essentially the most extreme and superior types of the illness. Pores and skin manifestations in RA embody rheumatoid nodules, rheumatoid vasculitis, pyoderma gangrenosum, rheumatoid neutrophilic dermatosis, and interstitial granulomatous dermatitis. Moreover, cutaneous reactions associated to RA therapies, specifically to organic brokers, are all reported within the literature. Early recognition of those manifestations by means of scientific and histological evaluation can expedite their prognosis and administration [2].

At present, there are quite a few medicines for the therapy of RA. These medicines are known as disease-modifying antirheumatic medication (DMARDs). They’ve each anti-inflammatory and immunomodulatory results, thus slowing the illness course of and stopping joint deformity. Amongst these medicines is a medicine known as tocilizumab [3].

Tocilizumab is a monoclonal humanized anti-Interleukin 6 (IL-6) receptor antibody, which has been accepted for the therapy of RA and has been proven to be extremely and quickly efficacious in bettering the scientific, biochemical, and radiographic parameters of the illness. Tocilizumab reduces illness exercise in RA by binding selectively to the elevated soluble and membrane-bound IL-6 receptors (IL-6Rs) within the serum and synovial fluid [4].

Tocilizumab is usually secure with tolerable adversarial reactions corresponding to gentle higher respiratory tract infections, hypertension, headache, hypercholesterolemia, and elevation of liver enzymes. Pores and skin manifestations corresponding to gentle maculopapular rash, urticaria, and pruritus are rare however noticeable secondary to tocilizumab remedy [5].

Herein, we report a case of tocilizumab-induced dermatosis in a affected person with RA.

Case Presentation

A 39-year-old girl, identified to have sort 1 diabetes mellitus for greater than 25 years, introduced to the rheumatology clinic with a four-month historical past of progressive inflammatory ache of a number of metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints bilaterally in addition to wrists and ankles. She had no different signs of systemic rheumatic ailments. Bodily examination revealed a number of tender and swollen MCP and PIP joints and left wrist, with no proof of deformity. Cardiac, belly, neurologic, and dermatologic examination was unremarkable. Laboratory investigations are proven in Desk one.

Take a look at outcomes Reference vary
Hemoglobin (Hb) 10.2 g/dL 12–15 g/dL
platelets 329×10^9/L 150–400 × 10^9/L
White blood cells (WBC) 5.95×10^9/L 4–11 × 10^9/L
Erythrocyte sedimentation charge (ESR) 30mm/h 3–10mm/h
C-reactive protein (CRP) 10mg/dL 0–0.3 mg/dL
RF 97 IU/mL 0–15.9 IU/mL
Anti-cyclic citrullinated peptide (CCP) Optimistic destructive
Antinuclear antibodies (ANA) destructive destructive

Based mostly on the laboratory investigations, she was identified with seropositive RA with excessive illness exercise and a Illness Exercise Rating (DAS)-28 C-reactive protein (CRP) rating of 5.14. She was began on a brief course of oral prednisolone at a dose of 15 mg each day with a fast taper, methotrexate 10 mg PO, and folic acid 5 mg PO as soon as weekly. Her methotrexate dose was then elevated regularly to fifteen mg. Common clinic follow-ups along with her de ella indicated full decision of her inflammatory arthritis with a DAS-28 CRP of two.2 at 9 months. Nevertheless, she reported ongoing nausea and epigastric ache, which she attributed to methotrexate. These unwanted effects interrupted her treatment compliance a number of instances. Modification within the therapy plan was mentioned along with her, methotrexate was discontinued, and tocilizumab was began at a dose of 4 mg/kg IV each 4 weeks.

After the second dose of tocilizumab, she introduced to the clinic with new onset maculopapular rash over her again, stomach, and arms with related itching and redness however no blistering or discharge (Determine one). She denied contact with any chemical substance or animal merchandise previous viral an infection or administration of a brand new treatment aside from tocilizumab. She will not be identified to have an allergy to meals, medication, or environmental triggers. Tocilizumab was held, and a referral to dermatology for additional evaluation was initiated. Pores and skin biopsy revealed orthokeratosis, hyperkeratosis, semiregular acanthosis with a outstanding granular layer, dilated capillaries within the higher dermis with perivascular lymphocytic infiltrate, and some eosinophils (Determine 2). For that, the scientific and histological findings have been consistent with drug-induced dermatosis secondary to tocilizumab.

Skin-biopsy-showing-hyperkeratosis-(A)-and-acanthosis-(B)-with-dilatation-of-blood-vessels-(orange-arrows)-and-presence-of-numerous-lymphocytes-(red-arrows) )-and-eosinophils-(green-arrows)

She returned to the rheumatology clinic after one month. Her pores and skin rash of hers resolved spontaneously; nonetheless, she was exhibiting flare in her RA de ella. Once more, a therapy plan was mentioned, and she or he determined to start out tofacitinib at a dose of 5 mg PO twice each day, which introduced her RA into remission in a single month.


A number of dermatological adversarial occasions are seen in sufferers taking tocilizumab [4]. These embody injection website reactions, gentle maculopapular rash, urticaria, pruritus, exanthematous pustulosis, and psoriasiform eruptions [5]. The vast majority of these manifestations are self-limiting and resolve upon tocilizumab discontinuation, and some require topical corticosteroid remedy. Our affected person developed tocilizumab-induced dermatosis.

Few instances of tocilizumab-induced pores and skin reactions have been reported within the literature. The primary case was a 79-year-old girl with seropositive RA for 20 years. She was handled for her extremely lively illness with gold, sodium thiomalate, hydroxychloroquine, leflunomide, azathioprine, methotrexate, etanercept, and adalimumab, all of which did not management her illness exercise. She was then began on tocilizumab plus oral prednisone. This therapy routine resulted in a major response, and her illness went into remission. After the sixth infusion of tocilizumab, she developed painful pustular psoriasiform eruptions on the again of each legs, the intergluteal cleft, behind the knees, and on the soles of her toes. Tocilizumab was discontinued, and these eruptions have been handled with topical corticosteroids. Her pores and skin rash improved after a number of weeks, however her arthritis flared ultimately, after which she was began on certolizumab, with good scientific response and no recurrence of her rash [6]. The second case was a 55-year-old girl with adult-onset Nonetheless’s illness. Her prognosis was based mostly on a historical past of spiking fevers, sore throat, arthralgia, evanescent maculopapular rash, leukocytosis, and elevated CRP and ferritin. Preliminary therapy with oral prednisolone and methotrexate failed to manage her signs of ella. For that, she was switched to tocilizumab monotherapy. Ten days later, she introduced with a diffuse pruritic maculopapular rash. Laboratory analysis revealed hyper-eosinophilia and elevations within the liver enzymes six instances the higher restrict of regular. Polymerase chain response check for human herpesvirus 6 was optimistic. Pores and skin biopsy outcomes confirmed lymphocytic and eosinophilic infiltration within the perivascular space. Tocilizumab was discontinued, and she or he was handled with topical corticosteroids. Pores and skin rash resolved after 5 weeks of stopping tocilizumab [7]. Tocilizumab has additionally been linked to the event of doable Stevens-Johnson syndrome in a affected person with big cell arteritis [8]psoriasiform rash in a number of sufferers [9]and drug-related generalized exanthematous pustulosis in a affected person with RA [10].

To the perfect of our information and in keeping with the literature evaluation, our case and the opposite above-mentioned instances display the event of dermatosis secondary to tocilizumab remedy.


Tocilizumab-induced dermatosis is a uncommon however rising dermatologic adversarial occasion. The etiopathology of dermatosis in the course of the IL-6 blockade is unclear however fascinating and requires additional exploration. This reversible adversarial response must be thought-about when treating sufferers with tocilizumab.

Leave a Reply

Your email address will not be published. Required fields are marked *